Navigation Links
OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference
Date:2/6/2013

SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon , President and CEO, will present at the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City, on Tuesday, February 12th at 3:00PM Eastern Time.

(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)

ABOUT THE BIO CEO & INVESTOR CONFERENCE
The 15th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies.  This year's conference will feature corporate presentations from more than 150 leading biotechnology and pharmaceutical companies, five Fireside Chats with industry leaders, three Therapeutic Workshops and five Business Roundtables all drawing from seasoned industry executives and analysts. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. To find out more information on the event, visit http://www.bio.org/events/conferences/bio-ceo-investor-conference

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. 


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical to Present at Noble Financial Capital Markets Ninth Annual Equity Conference on January 22
2. OncoSec Medical Announces $7.2 Million Public Offering
3. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
4. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
5. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
6. OncoSec to Present at Upcoming Healthcare and Investor Conferences
7. OncoSec Granted New Patent from China
8. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
9. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
10. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
11. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... N.J. , June 16, 2017 Datascope Corp. is ... by Datascope Corp. for a potential electrical test failure code.     ... PART NUMBER ... CS100 IABP CS300 IABP ... ...
(Date:6/13/2017)... WARSAW, Ind. , June 13, 2017 Zimmer ... in musculoskeletal healthcare, today announced that the U.S. Food and ... Letter dated June 3, 2015 relating to its ... "The successful clearance of ... China manufacturing facility is a measure of the ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 More ... a further effort to help spread lessons learned from ... the International Diabetes Federation (IDF) and Eli Lilly and ... for the second phase of the Bringing Research in ... reaffirming their commitment to helping people with diabetes effectively ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... 2017 , ... Two residents from the Gardant-managed assisted living and memory care ... encourage lawmakers to protect Medicaid funding. , The video, which was produced by the ... of Chuck and Cathy Schwarz, a couple who is still able to see each ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. ... Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance strategies of ... in these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced ...
(Date:6/27/2017)... Hollywood, CA (PRWEB) , ... June 27, 2017 ... ... orthodontic treatments . Orthodontics is a dental specialty that focuses on treating ... appliances. Benefits include improved aesthetics and function. , North Hollywood dentist ...
(Date:6/26/2017)... Houston, TX (PRWEB) , ... June 26, 2017 , ... Antoine Dental Center ... the gold standard in tooth replacement and act as a support for prosthetic teeth, such ... fuses with the existing bone and becomes a sturdy, lasting new root for the tooth. ...
(Date:6/26/2017)... Mexico (PRWEB) , ... June 26, 2017 , ... ... anorgasmia, and urinary leakage is revolutionizing the way women look and feel about ... tackling the problem of female sexual dysfunction and urinary leakage head on with ...
Breaking Medicine News(10 mins):